_1777370193195_831968492.png){kind=small}
_1777370220974_847775619.png){kind=small}
Wall Street Oversimplifies Cannabis Stocks
Despite a 104% recovery in cannabis stock prices over the past year, only seven U.S.-based cannabis companies generate over $100 million in adjusted EBITDA, making them the primary institutions capable of attracting meaningful investment. The industry faces challenges due to thin trading volumes, tax issues under federal law, and accounting practices that overstate profitability, with many companies experiencing negative cash flow despite positive EBITDA. Federal rescheduling of medical cannabis to Schedule III may ease tax burdens, but uncertainties remain about relief for past liabilities and the future of adult-use cannabis, likely demanding industry consolidation for further growth.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)